A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms

Kovrigina A.M.

doi:https://doi.org/10.17116/patol20188006143

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms

Authors:

Kovrigina A.M.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2018;80(6): 43‑49

DOI: 10.17116/patol20188006143

Read: 8798 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kovrigina AM. A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms. Russian Journal of Archive of Pathology. 2018;80(6):43‑49. (In Russ.)
https://doi.org/10.17116/patol20188006143

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper presents new molecular data, the principles of the classification of myeloid neoplasms, and criteria for their diagnosis according to the new edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017. Current concepts of clonal hematopoiesis and models of clonal evolution are presented to characterize the common features of the molecular pathogenesis of myeloid neoplasms. There are new data and general principles of diagnosis of myeloid neoplasms: Ph-negative myeloproliferative diseases, myelodysplastic syndromes, myeloid/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2, diseases from the group of myelodysplastic/myeloproliferative diseases. Emphasis is laid on the possibilities and limitations of pathological differential diagnosis when a pathologist examines bone marrow trepanobiopsy specimens in his/her routine work.

Keywords:

myeloid neoplasia

somatic mutation

clonal hematopoiesis

Ph-negative myeloproliferative diseases

myelodysplastic syndromes

Authors:

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

Close metadata

References:

WHO Classification of tumours of lymphoid and hematopoietic tissues. Lyon: IARC; 2017;585.
Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, Knudsen H, Ehinger M, Dahl‐Sørensen R, Mortensen NB, Svendsen KD, Lange T, Ralfkiaer E, Nielsen K, Hasselbalch HC, Thiele J. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations–the Danish experience. Am J Hematol. 2013;88(12):1012-1016. https://doi.org/10.1002/ajh.23554
Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E, Moro A, Valli R, Ponzoni M, M Florena A, F Orcioni G, Ascani S, Bonoldi E, Iurlo A, Gugliotta L, Franco V. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol. 2014;27(6):814-822. https://doi.org/10.1037/modpathol.2013.196
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, Kremer M, Schmitt-Graeff A, Schwarz S, Thiele J, Werner M, Stein H. Problems and pitfalls in grading of bone marrow ﬁbrosis,collagen deposition and osteosclerosis — a consensus-based study. Histopathology. 2016;68(6):905-915. https://doi.org/10.1111/his.12871
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542. https://doi.org/10.1002/cncr.22570
Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw. 2011;9(1):57-63. https://doi.org/10.6004/jnccn.2011.0006
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16. https://doi.org/10.1182/blood-2015-03-631747
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498. https://doi.org/10.1056/NEJMoa1408617
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, Dipersio JF, Chen F, Wilson RK, Ley TJ, Ding L. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 2014;20(12):1472-1478. https://doi.org/10.1038/nm.3733
Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487. https://doi.org/10.1056/NEJMoa1409405
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D, Suzuki H, Wu CO, Shiraishi Y, Clemente MJ, Kataoka K, Shiozawa Y, Okuno Y, Chiba K, Tanaka H, Nagata Y, Katagiri T, Kon A, Sanada M, Scheinberg P, Miyano S, Maciejewski JP, Nakao S, Young NS, Ogawa S. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35-47. https://doi.org/1056/NEJMoa1414799
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293-1296. https://doi.org/10.1182/blood-2013-10-531509
Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38. https://doi.org/10.1016/j.ccr.2011.06.003
Itzykson R, Kosmider O, Fenaux P. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2013;26(4):355-364. https://doi.org/10.1016/j.beha.2014.01.001
Ganguly BB, Kadam NN. Mutations of myelodysplastic syndromes (MDS): An update. Mutat Res Rev Mutat Res. 2016;769:47-62. https://doi.org/10.1016/j.mrrev.2016.04.009